Home › Neuroblastoma › California › Sacramento
Neuroblastoma clinical trials in Sacramento, CA
3 studies for Neuroblastoma are looking for participants at sites in and around Sacramento (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
- UC Davis Comprehensive Cancer Center, Sacramento
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
About Neuroblastoma
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
More about Neuroblastoma on MedlinePlus
Neuroblastoma trials in other cities
- Boston, MA13 studies
- New York City, NY12 studies
- Washington, DC11 studies
- Dallas, TX10 studies
- Cincinnati, OH9 studies
- St. Louis, MO9 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Aurora, CO9 studies
- Hartford, CT8 studies
- Birmingham, AL8 studies
- Harrisburg, PA8 studies
Other studies in Sacramento
- Non-Small Cell Lung Cancer29 studies
- Lung Cancer23 studies
- Prostate Cancer20 studies
- Breast Cancer19 studies
- Metastatic Cancer17 studies
- Acute Myeloid Leukemia12 studies
- Heart Failure12 studies
- Colon Cancer12 studies
- Cancer (all types)11 studies
- Colorectal Cancer11 studies
- Pancreatic Cancer11 studies
- Bladder Cancer10 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.